AIM Vaccine Submits Pre-Application for Serum-Free Rabies Vaccine
Key Insights
AIM Vaccine (search) has submitted a pre-application to the National Medical Products Administration for its iterative serum-free rabies (search) vaccine, potentially the first of its kind globally.
Phase III clinical trials demonstrated the vaccine's good safety, immunogenicity, and immune persistence, meeting pre-defined clinical objectives.
The serum-free formulation aims to reduce adverse reactions associated with animal serum residues found in traditional rabies vaccines (search).
AIM Vaccine (search) (06660.HK), the world’s second-largest supplier of rabies vaccines (search), announced the submission of a pre-application for marketing registration of its independently developed iterative serum-free rabies (search) vaccine to the National Medical Products Administration. This vaccine is poised to be the first serum-free rabies vaccine approved for launch globally.
The Phase III clinical trials have shown promising results, demonstrating good safety, immunogenicity, and immune persistence, successfully meeting the pre-defined clinical objectives. Unlike existing Vero cell rabies vaccines (search) and human diploid rabies vaccines that contain serum, AIM Vaccine (search)'s iterative serum-free rabies (search) vaccine is an advancement designed to eliminate animal serum residues, a significant factor in adverse reactions like allergies in vaccinated individuals. By excluding animal serum, the vaccine aims to significantly improve safety and reduce the probability of adverse reactions.
AIM Vaccine (search) has completed the construction of a state-of-the-art iterative serum-free rabies (search) vaccine workshop that meets international standards. The company has also completed commercial-scale validation production, confirming its capability to produce the vaccine on a large scale. This positions AIM Vaccine to play a crucial role in global public health by meeting the increasing demand for safer vaccines and enhancing its competitiveness in the global vaccine market.
Earlier this month, AIM Vaccine (search) also announced the submission of a drug marketing registration application for its independently developed 13-valent pneumonia conjugate vaccine (search), which has been accepted. The potential launch of these two vaccines is expected to drive substantial revenue growth for the company and further solidify its leadership in the biopharmaceutical industry.